NAMPT and cancer: Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), such as FK866, interfere with nicotinamide adenine dinucleotide (NAD+) biosynthesis and suppress therapy-induced senescent cancer stem-like cells [232].